Sheppard Pratt Health System

Sheppard Pratt Health System is a leading non-profit psychiatric hospital and health system in Towson, Maryland, home to the Center of Excellence for Psilocybin Research and Treatment — the first international center of its kind — established in partnership with COMPASS Pathways; it has conducted landmark psilocybin trials including the first trial for bipolar type II depression (published in JAMA Psychiatry with 80% remission at 12 weeks), psilocybin for treatment-resistant depression (published in NEJM), and psilocybin for TRD with chronic suicidal ideation.